HLA-B and toxic epidermal necrolysis: The risk of SJS/TEN among all patients commenced on CBZ (0.24%) combined with the prevalence of HLA-B*15∶02 (16.8%) and OR for HLA-B*15∶02-associated CBZ-SJS/TEN (89.25) allowed for estimation of risks of CBZ-SJS/TEN specifically among HLA-B*15∶02 carriers and non-carriers (see Formula 3 in Appendix S1).